New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GERN;HK;HWD;ISRG;MRO;ONTY;THLD;TROX;ZIOP;STRZA;XWES;NFLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
November 24, 2014
09:39 EDTNFLXActive equity options trading
Subscribe for More Information
09:26 EDTISRGFDA updates warning on laparoscopic power morcellators to treat uterine fibroids
The FDA announced it is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids. In an updated safety communication, originally issued in April, the FDA warns against using laparoscopic power morcellators in the removal of the uterus or fibroids in the vast majority of women. In an Immediately in Effect guidance, the FDA is also recommending that manufacturers of laparoscopic power morcellators include in their product labeling specific safety statements in the form of a boxed warning and two contraindications. Johnson & Johnson (JNJ), the largest manufacturer of morcellators, stopped selling the gynecological surgical tool in April and in August told customers to return any devices in their inventory. Intuitive Surgical's (ISRG) da Vinci surgical system can be used with tissue morcellators in such surgical procedures.
07:07 EDTSTRZAStarz seeking about $5B to sell itself, NY Post reports
Talks to buy Starz (STRZA) are "heating up," according to The New York Post. The company is said to be seeking about $5B, and the company has drawn interest from CBS (CBS) and Lionsgate (LGF), sources are saying. Reference Link
November 21, 2014
12:31 EDTNFLXAmazon.com looking to launch new video streaming service, NY Post says
Subscribe for More Information
10:50 EDTGERNGeron November volatility at low end of two-year range as shares trend higher
Geron December call option implied volatility is at 86, January is at 88, March is at 78; compared to its 26-week average of 106 according to Track Data, suggesting decreasing price risk.
06:01 EDTNFLXStocks with implied volatility below IV index mean; BHI NFLX
Subscribe for More Information
November 20, 2014
14:52 EDTNFLXNetflix to discuss future of TV with top industry executives, Re/code says
Netflix is holding a summit about the future of TV next month, according to Re/code The company invited many of the leading executives from the TV and film industries to the private event, the website added. Reference Link
06:48 EDTNFLXNetflix's Kelly Merryman to join YouTube, TechCrunch reports
Subscribe for More Information
06:39 EDTNFLXStocks with implied volatility below IV index mean; GNW NFLX
Stocks with implied volatility below IV index mean; Genworth (GNW) 53, Netflix (NFLX) 31 according to iVolatility.
November 19, 2014
19:16 EDTNFLXNetflix orders fourth season of Longmire
Subscribe for More Information
15:34 EDTSTRZALiberty Media CEO says focused on expanding cash reserves
Subscribe for More Information
14:25 EDTNFLXOptions Update; November 14, 2014
Subscribe for More Information
13:29 EDTNFLXCharter CEO sees Comcast, Time Warner Cable deal getting done
Subscribe for More Information
09:39 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:38 EDTNFLXCCS Insight predicts Netflix to be acquired next year, FT reports
CCS Insight, a U.K.-based technology research firm, is predicting that a major internet player such as Yahoo (YHOO), Alibaba (BABA) or Google (GOOG) will buy Netflix (NFLX) next year, reported Financial Times. Reference Link
06:34 EDTNFLXNielsen to begin measuring viewing of subscription video services, WSJ reports
Subscribe for More Information
06:00 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Stocks with implied volatility below IV index mean; Priceline (PCLN) 22, Netflix (NFLX) 29 according to iVolatility.
November 18, 2014
17:40 EDTNFLXNetflix to launch in Australia, New Zealand in March, 2015
Subscribe for More Information
05:57 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Stocks with implied volatility below IV index mean; Priceline (PCLN) 22, Netflix (NFLX) 30 according to iVolatility.
November 17, 2014
11:06 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:12 EDTMROBloomberg / Mayer Brown to co-host a conference
Subscribe for More Information
07:05 EDTTHLDThreshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data
Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months. In addition, the FDA, through its Office of Orphan Product Development, recently awarded Dr. Brenner a grant for a Phase 2 clinical trial of TH-302 for the treatment of GBM. His is one of 15 grants the FDA awarded in 2014 in order to boost the development of medical device, drug, and biological products for patients with rare diseases. According to the FDA, the grants are for clinical studies on safety and/or effectiveness of products that could either result in, or substantially contribute to, approval of the products.
November 14, 2014
17:07 EDTNFLXSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
17:01 EDTNFLXIcahn Associates gives quarterly update on stakes
Subscribe for More Information
16:21 EDTGERNOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTNFLXOptions Update; November 14, 2014
Subscribe for More Information
12:58 EDTGERNOn The Fly: Midday Wrap
Subscribe for More Information
12:48 EDTGERNGeron November volatility up on strategic collaboration with Janssen Biotech
Subscribe for More Information
11:37 EDTNFLXNetflix shuts down public API today, Gigaom reports
Subscribe for More Information
10:00 EDTGERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:12 EDTGERNGeron upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
06:19 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Subscribe for More Information
November 13, 2014
18:40 EDTGERNOn The Fly: After Hours Movers
UP AFTER EARNINGS: TubeMogul (TUBE), up 12.4%... Weibo (WB), up 3.2%... Nordstrom (JWN), up 3.1%. ALSO HIGHER: Geron (GERN), up 30.7% after announcing a global strategic collaboration with Janssen Biotech... Baker Hughes (BHI), up 16.2% following reports that the company is in talks to be acquired by Halliburton (HAL)... Halliburton is up 1.4%... Pandora (P), up 4% after announcing a conference call to discuss Web IV proceeding... AmerisourceBergen (ABC), up 1.1% after being awarded a $4.06B government contract. DOWN AFTER EARNINGS: Retrophin (RTRX), down 6.6%... Phoenix New Media (FENG), down 8.4%... Voxeljet AG (VJET), down 8.6%... Intrexon (XON), down 1.1%... Youku Tudou (YOKU), down 5.7%... Applied Materials (AMAT), down 2.5%. ALSO LOWER: Puma Biotechnology (PBYI), down 6.9% following PB272 Phase II Trial results... EnLink Midstream (ENLK), down 4.8% after filing to sell 10.5M common units representing limited partners.
16:28 EDTGERNGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
13:32 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
07:10 EDTTHLDSociety for NeuroOncology to hold a meeting
Subscribe for More Information
November 12, 2014
09:37 EDTNFLXActive equity options trading
Active equity options trading according to Track Data: AAPL CLSN TWTR BABA NFLX TSLA AMZN CSIQ C
08:18 EDTNFLXNetflix CFO expects to expand as much or 'bit more' next year, Bloomberg says
Netflix CFO David Wells said the company plans a “sizable expansion” into new markets next year, projecting expansion on the order of this year or "even potentially a little bit more,” reported Bloomberg, citing Wells' comments at an RBC Capital Markets conference. Reference Link
08:13 EDTZIOPBoston Biotech to hold a conference
Subscribe for More Information
07:31 EDTMROBofA/Merrill to hold a conference
Subscribe for More Information
November 11, 2014
16:14 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:01 EDTNFLXOptions Update; November 11, 2014
Subscribe for More Information
07:07 EDTTHLDThreshold Pharmaceuticals receives FDA fast track designation for TH-302
Threshold Pharmaceuticals announced that the FDA granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma, or STS. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. An important feature of Fast Track is that the FDA may consider a "rolling review" of completed sections of the New Drug Application before the complete application is submitted.
November 10, 2014
18:32 EDTHKOn The Fly: After Hours Movers
Subscribe for More Information
16:44 EDTNFLXOn The Fly: Closing Wrap
Subscribe for More Information
16:28 EDTONTYOncothyreon, Celldex announce initiation of ONT-10, varlilumab clinical trial
Oncothyreon Inc. (ONTY) and Celldex Therapeutics (CLDX) announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses, T-cell activation markers and levels of regulatory T-cells, and anti-tumor effects. The Phase 1b trial will be conducted by Oncothyreon under the terms of a previously announced collaboration agreement between Oncothyreon and Celldex. The two companies will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the agreement, neither company has granted the other a license, or any other rights, to its product candidate.
16:24 EDTXWESWorld Energy Solutions reports Q3 adjusted EPS 2c, consensus 1c
Subscribe for More Information
16:14 EDTHKHalcon Resources reports Q3 EPS 3c, consensus 6c
Subscribe for More Information
15:43 EDTMROAmerican Petroleum Institute to hold a conference
Subscribe for More Information
15:26 EDTHKNotable companies reporting after market close
Subscribe for More Information
14:09 EDTNFLXBoehner strongly opposes net neutrality
Subscribe for More Information
13:26 EDTNFLXCable providers fall after Obama weighs in on net neutrality
Subscribe for More Information
12:24 EDTNFLXOn The Fly: Midday Wrap
Stocks on Wall Street were modestly higher at midday. The averages opened mixed, but very close to the flat line, and have continued to drift slowly higher from that point. There is little to stand in the way of the market’s drift, as the economic calendar is quiet, the earnings season is winding down, and the most closely watched geopolitical situations are currently status quo. ECONOMIC EVENTS: In the U.S., little of note was on the economic calendar. The Federal Reserve's newly introduced Labor Market Conditions Index was flat at 4 in October. The Fed started updating estimates of the LMCI every month beginning with last month. COMPANY NEWS: Shares of Netflix (NFLX) advanced about 1% after xxx President Barack Obama publicly urged the Federal Communications Commission to implement the "strongest possible rules" to protect net neutrality. In response, Verizon (VZ) said it supports the open Internet and continues to believe that the "light-touch regulatory approach in place for the past two decades has been central to the Internet’s success," adding that it believes the reclassification Obama called for would "apply 1930s-era utility regulation to the Internet" and be a "radical reversal of course" that would threaten great harm to an open Internet, competition and innovation." A number of Internet Service Providers, including Comcast (CMCSA), Time Warner Cable (TWC), Charter (CHTR) and Cablevision (CVC), moved lower after Obama weighed in on the hot-button issue. MAJOR MOVERS: Among the notable gainers was Achillion Pharmaceuticals (ACHN), which rose 22% after the company presented data from the ongoing Phase 2 study of its Hepatitis C virus treatment at the Annual Meeting of the American Association for the Study of Liver Diseases, or AASLD. Also higher was Dean Foods (DF), which rose more than 13% after the dairy products distributor’s third quarter results, as well as its fourth quarter and full year profit outlook, surpassed analysts’ consensus estimates. Among the noteworthy losers was Rayonier (RYN), which dropped 13% after management determined that there was a material weakness in the company's internal controls, restated certain previously made financial statements, and cut its dividend reflecting expectations of reduced cash available for distribution due to lower expected annual harvest levels. INDEXES: Near midday, the Dow was up 18.55, or 0.11%, to 17,592.48, the Nasdaq was up 10.77, or 0.23%, to 4,643.30, and the S&P 500 was up 4.01, or 0.2%, to 2,035.93.
09:45 EDTNFLXObama urges FCC to enact 'strongest possible rules' to protect net neutrality
Subscribe for More Information
09:43 EDTNFLXObama urges FCC to enact 'strongest possible rules' to protect net neutrality
Subscribe for More Information
07:57 EDTISRGIntuitive Surgical survey positive on hernia opportunity, says JPMorgan
JPMorgan said its survey of 25 U.S.-based general surgeons who have used da Vinci for hernia procedures yielded positive outlook on the hernia opportunity for Intuitive Surgical. The firm says the complexity of the robot does not appear to be an issue. It keeps an Overweight rating on Intuitive with a $550 price target.
07:23 EDTNFLXRBC Capital to hold a conference
Subscribe for More Information
05:58 EDTNFLXStocks with implied volatility below IV index mean; CHK NFLX
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use